168 related articles for article (PubMed ID: 8328787)
21. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
O'Hare MD; Felmingham D; Grüneberg RN
Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of mersacidin (M87-1551), an investigational peptide antibiotic tested against gram-positive bloodstream isolates.
Barrett MS; Wenzel RP; Jones RN
Diagn Microbiol Infect Dis; 1992; 15(7):641-4. PubMed ID: 1424522
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
25. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
26. Enterococcal-type glycopeptide resistance genes in non-enterococcal organisms.
Patel R
FEMS Microbiol Lett; 2000 Apr; 185(1):1-7. PubMed ID: 10731599
[TBL] [Abstract][Full Text] [Related]
27. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
King A; Phillips I
J Antimicrob Chemother; 2001 Aug; 48(2):219-23. PubMed ID: 11481291
[TBL] [Abstract][Full Text] [Related]
28. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.
Jamjian C; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 1997 Feb; 41(2):454-9. PubMed ID: 9021207
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
Rolston KV; Kapadia M; Tarrand J; Coyle E; Prince RA
Int J Antimicrob Agents; 2013 Jun; 41(6):516-20. PubMed ID: 23481658
[TBL] [Abstract][Full Text] [Related]
30. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species.
Swenson JM; Facklam RR; Thornsberry C
Antimicrob Agents Chemother; 1990 Apr; 34(4):543-9. PubMed ID: 2344161
[TBL] [Abstract][Full Text] [Related]
32. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.
Maple PA; Hamilton-Miller JM; Brumfitt W
J Antimicrob Chemother; 1989 Apr; 23(4):517-25. PubMed ID: 2526111
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice.
Stiefel U; Pultz NJ; Helfand MS; Donskey CJ
Antimicrob Agents Chemother; 2004 Jun; 48(6):2144-8. PubMed ID: 15155213
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin.
Baden LR; Critchley IA; Sahm DF; So W; Gedde M; Porter S; Moellering RC; Eliopoulos G
J Clin Microbiol; 2002 Apr; 40(4):1160-3. PubMed ID: 11923325
[TBL] [Abstract][Full Text] [Related]
35. Treatment of experimental endocarditis caused by multidrug resistant Enterococcus faecium with ramoplanin and penicillin.
Landman D; Quale JM; Burney S; Kreiswirth B; Willey BM
J Antimicrob Chemother; 1996 Feb; 37(2):323-9. PubMed ID: 8707742
[TBL] [Abstract][Full Text] [Related]
36. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
37. European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates.
Goossens H; Jabes D; Rossi R; Lammens C; Privitera G; Courvalin P
J Antimicrob Chemother; 2003 Jun; 51 Suppl 3():iii5-12. PubMed ID: 12801937
[TBL] [Abstract][Full Text] [Related]
38. Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.
Cormican MG; Erwin ME; Jones RN
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):241-8. PubMed ID: 9458981
[TBL] [Abstract][Full Text] [Related]
39. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.
Mobarakai N; Quale JM; Landman D
Antimicrob Agents Chemother; 1994 Feb; 38(2):385-7. PubMed ID: 8192473
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
